Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY-NCAnnals of the Rheumatic Diseases

EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19

12 more authors

Abstract

OBJECTIVES: Severe systemic inflammation associated with some stages of COVID-19 and in fatal cases led therapeutic agents developed or used frequently in Rheumatology being at the vanguard of experimental therapeutics strategies. The aim of this project was to elaborate EULAR Points to consider (PtCs) on COVID-19 pathophysiology and immunomodulatory therapies. METHODS: PtCs were developed in accordance with EULAR standard operating procedures for endorsed recommendations, led by an international multidisciplinary Task Force, including rheumatologists, translational immunologists, haematologists, paediatricians, patients and health professionals, based on a systemic literature review up to 15 December 2020. Overarching principles (OPs) and PtCs were formulated and consolidated by formal voting. RESULTS: Two OPs and fourteen PtCs were developed. OPs highlight the heterogeneous clinical spectrum of SARS-CoV-2 infection and the need of a multifaceted approach to target the different pathophysiological mechanisms. PtCs 1-6 encompass the pathophysiology of SARS-CoV-2 including immune response, endothelial dysfunction and biomarkers. PtCs 7-14 focus on the management of SARS-CoV-2 infection with immunomodulators. There was evidence supporting the use of glucocorticoids, especially dexamethasone, in COVID-19 cases requiring oxygen therapy. No other immunomodulator demonstrated efficacy on mortality to date, with however inconsistent results for tocilizumab. Immunomodulatory therapy was not associated with higher infection rates. CONCLUSIONS: Multifactorial pathophysiological mechanisms, including immune abnormalities, play a key role in COVID-19. The efficacy of glucocorticoids in cases requiring oxygen therapy suggests that immunomodulatory treatment might be effective in COVID-19 subsets. Involvement of rheumatologists, as systemic inflammatory diseases experts, should continue in ongoing clinical trials delineating optimal immunomodulatory therapy utilisation in COVID-19.

Related

  1. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
    Alessia Alunno, Aurélie Najm, Pedro Machado +21
    Annals of the Rheumatic DiseasesPeer-reviewedLicence not stated39 citedImmunologyGeneral medicineHAL
  2. Points to consider for the reporting of variants of uncertain significance in germline genetic and genomic testing: A statement of the American College of Medical Genetics and Genomics (ACMG)
    Chloe E. Mighton, Aya Abu‐El‐Haija, Vimla Aggarwal +13
    Genetics in MedicinePeer-reviewedLicence not statedFull text20 citedGenetics & genomicsOpenAlex
  3. Immunomodulatory and targeted therapies for metastatic colorectal cancer
    Kuiliang Gao, Qianqian Lv, Lidan Zhao +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyCrossref
  4. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
    Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan Schirmer +24
    Annals of the Rheumatic DiseasesPeer-reviewedLicence not statedFull text906 citedImmunologyGeneral medicineHAL
  5. How do we monitor doxy-PEP impact and when should we consider revisiting guidelines?
    Yonatan H. Grad, Rachel Mittelstaedt, Remco P. H. Peters
    PLOS MedicinePeer-reviewedCC BY 4.0Full textMicrobiologyEpidemiology & public healthPLOSPMC
BibTeX
@article{alunno2026eular,
  title = {{EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19}},
  author = {Alessia Alunno and Aurélie Najm and Pedro Machado and Heidi Bertheussen and Gerd Burmester and Francesco Carubbi and Gabriele de Marco and Roberto Giacomelli and Olivier Hermine and John Isaacs and Isabelle Koné-Paut and César Magro-Checa and Iain Mcinnes and Pier Luigi Meroni and Luca Quartuccio and Athimalaipet Ramanan and Manuel Ramos-Casals and Javier Rodríguez Carrio and Hendrik Schulze-Koops and Tanja Stamm and Sander Tas and Benjamin Terrier and Dennis Mcgonagle and Xavier Mariette},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  month = nov,
  doi = {10.1136/annrheumdis-2020-219724},
  url = {https://hal.science/hal-05865060v1},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
AU  - Alessia Alunno
AU  - Aurélie Najm
AU  - Pedro Machado
AU  - Heidi Bertheussen
AU  - Gerd Burmester
AU  - Francesco Carubbi
AU  - Gabriele de Marco
AU  - Roberto Giacomelli
AU  - Olivier Hermine
AU  - John Isaacs
AU  - Isabelle Koné-Paut
AU  - César Magro-Checa
AU  - Iain Mcinnes
AU  - Pier Luigi Meroni
AU  - Luca Quartuccio
AU  - Athimalaipet Ramanan
AU  - Manuel Ramos-Casals
AU  - Javier Rodríguez Carrio
AU  - Hendrik Schulze-Koops
AU  - Tanja Stamm
AU  - Sander Tas
AU  - Benjamin Terrier
AU  - Dennis Mcgonagle
AU  - Xavier Mariette
PY  - 2026
DA  - 2026/11/15
JO  - Annals of the Rheumatic Diseases
DO  - 10.1136/annrheumdis-2020-219724
UR  - https://hal.science/hal-05865060v1
AB  - OBJECTIVES: Severe systemic inflammation associated with some stages of COVID-19 and in fatal cases led therapeutic agents developed or used frequently in Rheumatology being at the vanguard of experimental therapeutics strategies. The aim of this project was to elaborate EULAR Points to consider (PtCs) on COVID-19 pathophysiology and immunomodulatory therapies. METHODS: PtCs were developed in accordance with EULAR standard operating procedures for endorsed recommendations, led by an international multidisciplinary Task Force, including rheumatologists, translational immunologists, haematologists, paediatricians, patients and health professionals, based on a systemic literature review up to 15 December 2020. Overarching principles (OPs) and PtCs were formulated and consolidated by formal voting. RESULTS: Two OPs and fourteen PtCs were developed. OPs highlight the heterogeneous clinical spectrum of SARS-CoV-2 infection and the need of a multifaceted approach to target the different pathophysiological mechanisms. PtCs 1-6 encompass the pathophysiology of SARS-CoV-2 including immune response, endothelial dysfunction and biomarkers. PtCs 7-14 focus on the management of SARS-CoV-2 infection with immunomodulators. There was evidence supporting the use of glucocorticoids, especially dexamethasone, in COVID-19 cases requiring oxygen therapy. No other immunomodulator demonstrated efficacy on mortality to date, with however inconsistent results for tocilizumab. Immunomodulatory therapy was not associated with higher infection rates. CONCLUSIONS: Multifactorial pathophysiological mechanisms, including immune abnormalities, play a key role in COVID-19. The efficacy of glucocorticoids in cases requiring oxygen therapy suggests that immunomodulatory treatment might be effective in COVID-19 subsets. Involvement of rheumatologists, as systemic inflammatory diseases experts, should continue in ongoing clinical trials delineating optimal immunomodulatory therapy utilisation in COVID-19.
SN  - 0003-4967
SN  - 1468-2060
ER  -